Drug resistance missense mutations in cancer are subject to evolutionary constraints.

ABSTRACT: Several tumour types are sensitive to deactivation of just one or very few genes that are constantly active in the cancer cells, a phenomenon that is termed 'oncogene addiction'. Drugs that target the products of those oncogenes can yield a temporary relief, and even complete remission. Unfortunately, many patients receiving oncogene-targeted therapies relapse on treatment. This often happens due to somatic mutations in the oncogene ('resistance mutations'). 'Compound mutations', which in the context of cancer drug resistance are defined as two or more mutations of the drug target in the same clone may lead to enhanced resistance against the most selective inhibitors. Here, it is shown that the vast majority of the resistance mutations occurring in cancer patients treated with tyrosin kina

SUBMITTER: Friedman R 

PROVIDER: S-EPMC3869674 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature